Pascal Jabbour

Dr. Pascal Jabbour

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
WDWilliam S Dodd
William S Dodd
DLDimitri Laurent
Dimitri Laurent
ADAaron S. Dumont
Aaron S. Dumont
DHDavid Hasan
David Hasan
PJPascal Jabbour
Pascal Jabbour
NCNohra Chalouhi
Nohra Chalouhi
Delayed cerebral ischemia is a major predictor of poor outcomes in patients who suffer subarachnoid hemorrhage. Treatment options are limited and often ineffective despite many years of investigation and clinical trials. Modern advances in basic science have produced a much more complex, multifactorial framework in which delayed cerebral ischemia is better understood and novel treatments can be developed. Leveraging this knowledge to improve outcomes, however, depends on a holistic understanding of the disease process. We conducted a review of the literature to analyze the current state of investigation into delayed cerebral ischemia with emphasis on the major themes that have emerged over the past decades. Specifically, we discuss microcirculatory dysfunction, glymphatic impairment, inflammation, and neuroelectric disruption as pathological factors in addition to the canonical focus on cerebral vasospasm. This review intends to give clinicians and researchers a summary of the foundations of delayed cerebral ischemia pathophysiology while also underscoring the interactions and interdependencies between pathological factors. Through this overview, we also highlight the advances in translational studies and potential future therapeutic opportunities.

30 April 2020 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
FSFadi Al Saiegh
Fadi Al Saiegh
RGRitam Ghosh
Ritam Ghosh
ALAdam Leibold
Adam Leibold
MAMichael B Avery
Michael B Avery
RSRichard F Schmidt
Richard F Schmidt
MGM. Reid Gooch
M. Reid Gooch
Background Emergence of the novel corona virus (severe acute respiratory syndrome (SARS)-CoV-2) in December 2019 has led to the COVID-19 pandemic. The extent of COVID-19 involvement in the central nervous system is not well established, and the presence or the absence of SARS-CoV-2 particles in the cerebrospinal fluid (CSF) is a topic of debate. Case description We present two patients with COVID-19 and concurrent neurological symptoms. Our first patient is a 31-year-old man who had flu-like symptoms due to COVID-19 and later developed an acute-onset severe headache and loss of consciousness and was diagnosed with a Hunt and Hess grade 3 subarachnoid haemorrhage from a ruptured aneurysm. Our second patient is a 62-year-old woman who had an ischaemic stroke with massive haemorrhagic conversion requiring a decompressive hemicraniectomy. Both patients’ CSF was repeatedly negative on real-time PCR analysis despite concurrent neurological disease. Conclusion Our report shows that patients’ CSF may be devoid of viral particles even when they test positive for COVID-19 on a nasal swab. Whether SARS-CoV-2 is present in CSF may depend on the systemic disease severity and the degree of the virus’ nervous tissue tropism and should be examined in future studies.

21 September 2012 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
DHDavid Hasan
David Hasan
NCNohra Chalouhi
Nohra Chalouhi
PJPascal Jabbour
Pascal Jabbour
THTomoki Hashimoto
Tomoki Hashimoto
M1 and M2 cells are two major subsets of human macrophages that exert opposite effects on the inflammatory response. This study aims to investigate the role of macrophage M1/M2 imbalance and mast cells in the progression of human cerebral aneurysms to rupture. Ten patients with cerebral aneurysms (five ruptured and five unruptured) underwent microsurgical clipping. During the procedure, a segment of the aneurysm dome was resected and immunostained with monoclonal antibodies for M1 cells (anti-HLA DR), M2 cells (anti-CD 163), and mast cells (anti-tryptase clone AA). A segment of the superficial temporal artery (STA) was also removed and immunostained with monoclonal antibodies for M1, M2, and mast cells. All ten aneurysm tissues stained positive for M1, M2, and mast cells. M1 and M2 cells were present in equal proportions in unruptured aneurysms. This contrasted with a marked predominance of M1 over M2 cells in ruptured aneurysms (p = 0.045). Mast cells were also prominently upregulated in ruptured aneurysms (p = 0.001). Few M1 and M2 cells were present in STA samples. M1/M2 macrophages and mast cells are found in human cerebral aneurysms; however, M1 and mast cell expression seems to markedly increase in ruptured aneurysms. These findings suggest that macrophage M1/M2 imbalance and upregulation of mast cells may have a role in the progression of cerebral aneurysms to rupture.

5 January 2015 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
NMNikolaos Mouchtouris
Nikolaos Mouchtouris
NCNohra Chalouhi
Nohra Chalouhi
ACAmeet Chitale
Ameet Chitale
RSRobert M Starke
Robert M Starke
STStavropoula I Tjoumakaris
Stavropoula I Tjoumakaris
PJPascal Jabbour
Pascal Jabbour
Cerebral cavernous malformations are the most common vascular malformations and can be found in many locations in the brain. If left untreated, cavernomas may lead to intracerebral hemorrhage, seizures, focal neurological deficits, or headaches. As they are angiographically occult, their diagnosis relies on various MR imaging techniques, which detect different characteristics of the lesions as well as aiding in planning the surgical treatment. The clinical presentation and the location of the lesion are the most important factors involved in determining the optimal course of treatment of cavernomas. We concisely review the literature and discuss the advantages and limitations of each of the three available methods of treatment—microsurgical resection, stereotactic radiosurgery, and conservative management—depending on the lesion characteristics.

1 October 2019 in World Neurosurgery
Verified
Journal Article
Closed access
PTPavlos Texakalidis
Pavlos Texakalidis
ASAhmad Sweid
Ahmad Sweid
NMNikolaos Mouchtouris
Nikolaos Mouchtouris
EPEric C. Peterson
Eric C. Peterson
Chrissa SiokaChrissa Sioka
Chrissa Sioka
PJPascal Jabbour
Pascal Jabbour

1 July 2013 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
PJPascal Jabbour
Pascal Jabbour
NCNohra Chalouhi
Nohra Chalouhi
STStavropoula Tjoumakaris
Stavropoula Tjoumakaris
LGL. Fernando Gonzalez
L. Fernando Gonzalez
ADAaron S. Dumont
Aaron S. Dumont
RRRobert Rosenwasser
Robert Rosenwasser
BACKGROUND:. The Pipeline Embolization Device (PED) has emerged as a promising treatment for intracranial aneurysms.OBJECTIVE:. To assess the safety and